Comparative Pharmacology
Head-to-head clinical analysis: GUANFACINE HYDROCHLORIDE versus IOPIDINE.
Peer-Reviewed Evidence
Head-to-head clinical analysis: GUANFACINE HYDROCHLORIDE versus IOPIDINE.
GUANFACINE HYDROCHLORIDE vs IOPIDINE
Comparing the clinical profiles, pharmacokinetic behaviors, and safety indices of these two therapeutic agents.
Selective alpha-2A adrenergic receptor agonist, reducing sympathetic outflow from the CNS, decreasing peripheral vascular resistance and heart rate.
Alpha-2 adrenergic agonist; reduces intraocular pressure by decreasing aqueous humor production and increasing uveoscleral outflow.
Immediate-release: 0.5-2 mg orally once daily at bedtime, titrated from 0.5 mg/day. Extended-release (ER): 1-4 mg orally once daily at bedtime, titrated from 1 mg/day.
Adults: 1 drop of 0.5% or 1% ophthalmic solution in the affected eye(s) three times daily, beginning 48 hours prior to surgery and continuing on the day of surgery. Alternatively, for intraocular surgery, 1 drop of 1% solution is administered 1 hour before surgery and 1 drop immediately after surgery.
None Documented
None Documented
Terminal elimination half-life is 17 hours (range 10–30 hours) in healthy adults; extends to 24–36 hours in chronic kidney disease.
0.5-2 hours (terminal) for topical ophthalmic administration; clinical effect may persist longer due to local tissue binding.
Renal excretion accounts for approximately 80% of the dose (40-50% unchanged, remainder as metabolites); fecal elimination is about 20%.
Renal excretion (% unchanged drug not determined; metabolites excreted renally)
Category A/B
Category C
Alpha-2 Agonist
Alpha-2 Agonist